Investor Presentation Full Year 2017
R&D milestones in 2018
Project
TresibaⓇ
XultophyⓇ
FiaspⓇ
OzempicⓇ
oral semaglutide
Q1 2018
DEVOTE and SWITCH
US regulatory decision
DUAL I Japan Phase 3a
DUAL II Japan Phase 3a ✓
EU and Japan regulatory
Investor Presentation
Full year 2017
Slide 15
Results available¹
Regulatory milestone
Q2 2018
Q3 2018
Japan submission
Japan submission
Q4 2018
TresibaⓇ vs insulin
glargine U300 data
decision
PIONEER 1 data
PIONEER 2, 3, 4 and 7
data
PIONEER 5 and 10 data
PIONEER 6, 8 and 9
data
LAI287
Phase 1 data
G530L
Phase 1 data
AM833
Phase 1 data
N8-GP
US/EU submission
N9-GP
Japan submission
Japan regulatory decision
concizumab
somapacitan
Diabetes
Obesity
Haemophilia
explorer 5 data
explorer 4 data
REAL 3 data
REAL 1 AGHD data
Growth disorders
1 Expected to be published in the given quarter or in the subsequent quarterly company announcement
AGHD: Adult growth hormone deficiency
novo nordiskView entire presentation